Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF)(„BioVaxys" oder „da Unternehmen") hat heute bekannt gegeben, dass eine Übereinkunft mit ...
BioVaxys Technology Corp. (CSE: BIOV ; FRA: 5LB ; OTCQB: BVAXF) (« BioVaxys » ou la « Société »), a annoncé aujourd'hui que les Hospices Civils de...
BioVaxys Technology Corp. (CSE: BIOV; FRA: 5LB; OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that Hospices Civils de Lyon, France ("HCL") ...
BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" oder „Unternehmen"), gab heute bekannt, dass das Unternehmen die...
BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has continued to expand the patent ...
BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that Mr. Anthony Dutton has been...
BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or "Company"), announced today that it has entered into an agreement with the ...
BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) („BioVaxys" oder „Unternehmen") gab heute die Erweiterung seiner...
BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) (« BioVaxys » ou la « Société ») a annoncé aujourd'hui l'expansion de sa plateforme ...
BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" o "la compañía"), anunció hoy la expansión de su plataforma de vacunas...
BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today the expansion of its cancer vaccine...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (« BioVaxys » ou la « Société »), a annoncé aujourd'hui la conclusion avec...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder das „Unternehmen"), hat heute bekannt gegeben, eine Vereinbarung mit ...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" o la "Compañía"), anunció hoy que ha llegado a un acuerdo con...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has entered into an agreement with ...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the second...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) („BioVaxys" oder „Unternehmen") hat heute bekannt gegeben, dass Studien zu BVX-0320,...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAX) ("BioVaxys" or "Company") announced today that studies on BVX-0320, its haptenized...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce that it has closed the first...
BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private...
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) („BioVaxys" oder das „Unternehmen"), ein Immuntherapie-Unternehmen für klinische...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.